Nemolizumab for treating prurigo nodularis [ID6451]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 May 2025
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC